An Integrated Genomic Analysis of Human Glioblastoma Multiforme

Комплексный геномный анализ мультиформной глиобластомы человека
Donald Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Lin, Rebecca J. Leary, Philipp Angenendt, Parminder K. Mankoo, Hannah K. Carter, I‐Mei Siu, Gary L. Gallia, Alessandro Olivi, Roger E. McLendon, B. Ahmed Rasheed, Stephen Thomas Keir, Tatiana Nikolskaya, Yuri Nikolsky, Dana Busam, Hanna Tekleab, Luis Alberto Diaz, James Hartigan, Doug R. Smith, Robert L. Strausberg, Suely Kazue Nagahashi Marie, Sueli Mieko Oba‐Shinjo, Hai Yan, Gregory Joseph Riggins, Darell D. Bigner, Rachel Karchin, Nick Papadopoulos, Giovanni Parmigiani, Bert Vogelstein, Victor E. Velculescu, Kenneth W. Kinzler
2008-09-04

Copy number alterationsGene expression analysisGlioblastoma multiformeIDH1 mutationsIntegrated genomic analysis
Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer. To identify the genetic alterations in GBMs, we sequenced 20,661 protein coding genes, determined the presence of amplifications and deletions using high-density oligonucleotide arrays, and performed gene expression analyses using next-generation sequencing technologies in 22 human tumor samples. This comprehensive analysis led to the discovery of a variety of genes that were not known to be altered in GBMs. Most notably, we found recurrent mutations in the active site of isocitrate dehydrogenase 1 (IDH1) in 12% of GBM patients. Mutations in IDH1 occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival. These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs.
1
An integrated analysis of 22 human GBM tumors combined sequencing of 20,661 protein-coding genes, copy-number profiling, and gene-expression analysis.
2
IDH1 mutations were associated with increased overall survival, supporting their potential use in GBM classification and targeted therapy.
3
IDH1 mutations were frequent among younger patients and present in most secondary GBMs.
4
Recurrent mutations in the active site of IDH1 occurred in 12% of GBM patients.
5
The comprehensive genomic analysis identified multiple genes not previously known to be altered in glioblastoma multiforme.

human glioblastoma multiforme (GBM) tumors

genetic alterations, particularly recurrent IDH1 active-site mutations and their associations with patient age, secondary GBM status, overall survival, classification, and targeted therapy

Publication Details
Publication Date
2008-09-04
Journal
Science
Publisher
American Association for the Advancement of Science
ISSN
0036-8075
Cited by
6501
Access Type
Author Information
Authors
Donald Williams Parsons
Siân Jones
Xiaosong Zhang
Jimmy Lin
Rebecca J. Leary
Philipp Angenendt
Parminder K. Mankoo
Hannah K. Carter
I‐Mei Siu
Gary L. Gallia
Alessandro Olivi
Roger E. McLendon
B. Ahmed Rasheed
Stephen Thomas Keir
Tatiana Nikolskaya
Yuri Nikolsky
Dana Busam
Hanna Tekleab
Luis Alberto Diaz
James Hartigan
Doug R. Smith
Robert L. Strausberg
Suely Kazue Nagahashi Marie
Sueli Mieko Oba‐Shinjo
Hai Yan
Gregory Joseph Riggins
Darell D. Bigner
Rachel Karchin
Nick Papadopoulos
Giovanni Parmigiani
Bert Vogelstein
Victor E. Velculescu
Kenneth W. Kinzler
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%